Mass. Medicaid Advises Against Zyprexa First Line, But No Prior Authorization
Executive Summary
Massachusetts Medicaid is advising physicians against use of Lilly's atypical antipsychotic Zyprexa (olanzapine) as first-line therapy
You may also be interested in...
Texas Medicaid Restricts Zyprexa Use; Effect To Stabilize Soon, Lilly Says
The impact of Texas Medicaid's decision to require prior authorization for Zyprexa will stabilize after about six months, Lilly Investor Relations Manager Heidi Straub said April 19
Texas Medicaid Restricts Zyprexa Use; Effect To Stabilize Soon, Lilly Says
The impact of Texas Medicaid's decision to require prior authorization for Zyprexa will stabilize after about six months, Lilly Investor Relations Manager Heidi Straub said April 19
Crestor Impact Review To Precede Mass. Medicaid Preferred Statin Decision
Massachusetts Medicaid will assess the market impact of AstraZeneca's Crestor (rosuvastatin) before selecting a preferred statin for the program